Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
Covered in this story
Call it yourself
No calls on $VRCA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Verrica Pharmaceuticals →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.